Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-054210
Filing Date
2020-11-16
Accepted
2020-11-16 17:02:01
Documents
58
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvus-10q_20200930.htm 10-Q 2410669
2 EX-31.1 nvus-ex311_6.htm EX-31.1 11430
3 EX-31.2 nvus-ex312_9.htm EX-31.2 11493
4 EX-32.1 nvus-ex321_8.htm EX-32.1 7498
5 EX-32.2 nvus-ex322_7.htm EX-32.2 7869
  Complete submission text file 0001564590-20-054210.txt   7256778

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nvus-20200930.xml EX-101.INS 1336286
7 XBRL TAXONOMY EXTENSION SCHEMA nvus-20200930.xsd EX-101.SCH 61836
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nvus-20200930_cal.xml EX-101.CAL 47474
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nvus-20200930_def.xml EX-101.DEF 176376
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvus-20200930_lab.xml EX-101.LAB 400659
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvus-20200930_pre.xml EX-101.PRE 315607
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 201318143
SIC: 2834 Pharmaceutical Preparations